Combining the checkpoint inhibitor atezolizumab with targeted therapy led to improvements in overall survival in patients ...

Researchers aimed to evaluate the efficacy of combining atezolizumab with targeted therapy based on tumor mutation status.

Bevacizumab in combination with atezolizumab and chemotherapy led to improvements in progression-free survival and duration ...

Atezolizumab did not improve overall survival, progression-free survival, distant metastasis-free survival, or time to local failure.

This group got a combination of atezolizumab plus cobimetinib, but overall median survival was much shorter, just 8.7 months.

Citing a Feb. 14 data cut, the Brisbane, California-based biotech said amezalpat led to a six-month survival advantage with cancer drugs atezolizumab and bevacizumab, marketed as Tecentriq and ...

Mutation-directed targeted therapy in combination with a PD-L1 inhibitor “is a promising strategy” to extend survival in patients with anaplastic thyroid cancer, according to researchers.

Xilio Therapeutic announced initial clinical data from its ongoing Phase 1C clinical trial evaluating vilastobart, a tumor-activated, ...

A clinical trial at MD Anderson Cancer Center reveals promising results for anaplastic thyroid carcinoma (ATC) patients.

Clinical trials of single-agent targeted drugs have shown limited efficacy. In the only trial of single-agent immunotherapy ...

Will present initial Phase 1C dose escalation data for vilastobart (XTX101), a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with ...

BRISBANE, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated ...